(HealthDay)—Atenolol is associated with a reduction in incident intermediate- and low-risk prostate cancer (PCa), according to a study presented at the annual meeting of the American Urological Association, held from May 3 to 6 in Chicago. Ali Zahalka, M.D., Ph.D., from the Albert Einstein College of Medicine and Montefiore Medical Center in Bronx, New York, and colleagues conducted a retrospective […]

Continue reading »